Quick Answer
Sarepta Therapeutics, Inc. reported Operating Income of -$699.78 million for fiscal year 2025.
Sarepta Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$699.78M | -420.9% |
| 2024 | $218.08M | +181.4% |
| 2023 | -$267.82M | +50.1% |
| 2022 | -$536.20M | -16.6% |
| 2021 | -$459.71M | +18.5% |
| 2020 | -$564.16M | +20.0% |
| 2019 | -$705.56M | -105.3% |
| 2018 | -$343.63M | -100.2% |
| 2017 | -$171.64M | +35.7% |
| 2016 | -$266.73M | -21.1% |
| 2015 | -$220.18M | -64.6% |
| 2014 | -$133.79M | -48.2% |
| 2013 | -$90.28M | -204.0% |
| 2012 | -$29.70M | +17.3% |
| 2011 | -$35.93M | -71.6% |
| 2010 | -$20.93M | -35.0% |
| 2009 | -$15.51M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$103.39M | -565.8% | -189.5% |
| June 30, 2025 | $115.58M | +16587.4% | +138.5% |
| March 31, 2025 | -$300.39M | -960.6% | -1453.3% |
| September 30, 2024 | $22.20M | +206.5% | +3266.3% |
| June 30, 2024 | -$701.0K | +99.5% | -102.0% |
| March 31, 2024 | $34.91M | +125.3% | +267.5% |
| September 30, 2023 | -$20.84M | +84.1% | +84.4% |
| June 30, 2023 | -$133.52M | +36.8% | +3.3% |
- Sarepta Therapeutics, Inc. showed a decrease of -420.9% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Sarepta Therapeutics, Inc.’s operating income has declined by 4412.7% (from -$15.51 million to -$699.78 million).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: